Keratosis pilaris caused by dupilumab for the treatment of bronchial asthma
Abstract Here, we present two patients with bronchial asthma, who developed keratosis pilaris (KP) following treatment with dupilumab, a monoclonal antibody to IL‐4 receptor. Both of them reported pruritic papules in their extremities in 1 months after initiation of dupilumab therapy. The lesions ne...
Guardado en:
Autores principales: | , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4710040ae2894f3f9200982a22409a58 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Sumario: | Abstract Here, we present two patients with bronchial asthma, who developed keratosis pilaris (KP) following treatment with dupilumab, a monoclonal antibody to IL‐4 receptor. Both of them reported pruritic papules in their extremities in 1 months after initiation of dupilumab therapy. The lesions newly developed on the day of every administration of dupilumab at 2‐week interval, however, they tended to resolve over time until the next treatment. A diagnosis of KP was made from clinical and histopathologic findings. Dermoscopic examination revealed keratotic plugs with coiled, curly hairs. We suspected that dupilumab might abruptly impact on growth of vellus hair to generate KP. |
---|